

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

NCT05067348

Status	RECRUITING
Phase	Phase 2
Sponsor	Tang-Du Hospital
Enrollment	64 participants

Key Eligibility Criteria

Inclusion (7)

- Diagnosis of MG with anti-AChR antibody.
- MGFA Clinical Classification Class II, III, or IV.
- MG-ADL score of 5 or greater at screening and at randomization with > 50% of this score attributed to non-ocular items.
- QMG score of 11 or greater.
- Subjects must be on:

... and 2 more (see full listing online)

Exclusion (9)

- Participants had clinically relevant active infections (such as sepsis, pneumonia, or abscess) or severe infections (resulting in hospitalization or requiring antibiotic treatment) in the 4 weeks before randomization;
- Those with a history of high-risk tuberculosis infection, acquired tuberculosis infection, and chronic hepatitis;
- Human immunodeficiency virus (HIV) infection;
- Thymomas that have received thymectomy or planned thymectomy during RCP within 6 months before randomization, or require chemotherapy and/or radiotherapy at any time;
- Received rituximab treatment in the past 6 months before randomization;

... and 4 more (see full listing online)

Locations (6 total)

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Xiangya Hospital Central South University, Changsha, Hunan, China
Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China
... and 3 more locations